vancosan 1000 mg infusioonilahuse pulber
mip pharma gmbh - vankomütsiin - infusioonilahuse pulber - 1000mg 1tk; 1000mg 10tk; 1000mg 5tk
vancosan 500 mg infusioonilahuse pulber
mip pharma gmbh - vankomütsiin - infusioonilahuse pulber - 500mg 10tk; 500mg 5tk; 500mg 1tk
geroxynal toimeainet prolongeeritult vabastav tablett
g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 10tk; 10mg+5mg 50tk; 10mg+5mg 14tk; 10mg+5mg 30tk; 10mg+5mg 60tk
geroxynal toimeainet prolongeeritult vabastav tablett
g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 40mg+20mg 30tk; 40mg+20mg 7tk; 40mg+20mg 20tk; 40mg+20mg 14tk; 40mg+20mg 100tk; 40mg+20mg 28tk; 40mg+20mg 10tk
vancomycin kabi 500mg infusioonilahuse kontsentraadi pulber
fresenius kabi polska sp. z o.o. - vankomütsiin - infusioonilahuse kontsentraadi pulber - 500mg 10tk; 500mg 1tk
fludarabine ebewe" 25mg/ml" süste-/infusioonilahuse kontsentraat
sandoz pharmaceuticals d.d. - fludarabiin - süste-/infusioonilahuse kontsentraat - 25mg 1ml 2ml 1tk; 25mg 1ml 2ml 5tk; 25mg 1ml 2ml 10tk
fludarabine actavis süste-/infusioonilahuse kontsentraat
actavis group ptc ehf. - fludarabiin - süste-/infusioonilahuse kontsentraat - 25mg 1ml 2ml 5tk
xofluza
roche registration gmbh - baloxavir marboxil - gripp, inimene - viirusevastased ravimid süsteemseks kasutamiseks - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.
vaxneuvance
merck sharp & dohme b.v. - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokoki infektsioonid - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. vt lõigud 4. 4 ja 5. 1, mis käsitleb kaitset spetsiifiliste pneumokokkide serotüüpide eest. the use of vaxneuvance should be in accordance with official recommendations.
levodopa/carbidopa fairmed tablett
fairmed healthcare gmbh - levodopa+karbidopa - tablett - 100mg+25mg 100tk; 100mg+25mg 20tk; 100mg+25mg 200tk